T0	Participants 47 159	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
T1	Participants 175 227	36 patients treated in France in the RECORD-1 Trial.
T2	Participants 286 338	patients with metastatic renal cell carcinoma (mRCC)
T3	Participants 561 627	patients with disease progression after a TKI-everolimus sequence.
T4	Participants 672 777	patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites.
T5	Participants 860 912	patients treated with a TKI-everolimus-TKI sequence.
T6	Participants 921 940	Thirty-six patients